MedPath
HSA Approval

STERI-NEB IPRATROPIUM NEBULISER SOLUTION 250 mcg/ml

SIN10039P

STERI-NEB IPRATROPIUM NEBULISER SOLUTION 250 mcg/ml

STERI-NEB IPRATROPIUM NEBULISER SOLUTION 250 mcg/ml

September 17, 1998

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Licence HolderTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

SOLUTION

NASAL

Medical Information

R03BB01

ipratropium bromide

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

IVAX PHARMACEUTICALS UK

Active Ingredients

IPRATROPIUM BROMIDE

250 mcg/ml

Ipratropium

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

STERI-NEB IPRATROPIUM NEBULISER SOLUTION 250 mcg/ml - HSA Approval | MedPath